With public equity investors unwilling to put money into early-stage biotech companies, the pressure to compile a stable of marketed and late-stage products can lead to business combinations that aren't driven by technology.

RiboGene Inc. and Cypros Pharmaceutical Corp. hope that through their merger plan announced last week, the combination of RBO's cash - $26 million as of June 30 - with CYP's marketed products, plus a merged pipeline and new-found ability to ramp-up sales will catch the attention of investors (see B3).